BUSCOFEN 200 MG
Anti-inflammatory and antirheumatic product, non-steroidal. Propionic acid and derivatives.
Coated tablets: 1 tablet contains: ibuprofen 200 mg. Soft gelatin capsules: 1 soft capsule contains: ibuprofen 200 mg.
Coated tablets, blister packs of 20 tablets: corn starch, sodium carboxymethyl starch, magnesium stearate, hydroxypropyl methylcellulose, polyethylene glycol 6000, talc, titanium dioxide, antifoam emulsion. Soft capsules, blisters of 12 or 24 capsules: macrogol 600, potassium hydroxide, purified water, gelatin, partially dehydrated liquid sorbitol.
Pain of various origins and nature (menstrual pain, headache, bad teeth, neuralgia, osteoarticular and muscle pain).
CONTRAINDICATIONS / EFF.SECONDAR
Hypersensitivity 'to the active substance or to any of the excipients. Subjects with hypersensitivity to acetylsalicylic acid or other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs (NSAIDs), in particular when hypersensitivity is associated with nasal polyposis, angioedema and / or asthma. Severe liver failure. Renal failure (glomerural filtration less than 30 ml / min). Severe heart failure (12th class NYHA). Subjects with blood dyscrasias of unknown origin, porphyria, hypertension, severe uncontrolled coronary insufficiency. Severe or active peptic ulcer. History of gastrointestinal bleeding or perforation related to previous active treatments or history of recurrent peptic hemorrhage / ulcer (two or more distinct episodes of demonstrated ulceration or bleeding). Subjects with clinical conditions that cause an increase in bleeding tendency. In conjunction with surgery (including dental operations). Subjects who have suffered significant fluid loss (due to vomiting, diarrhea or poor fluid ingestion). During the third trimester of pregnancy. Children under XNUMX years old.
Do not administer to children under the age of 12. The undesirable effects can be minimized with the use of the lowest effective dose for the shortest possible duration of treatment needed to control symptoms. Coated tablets. Adults and adolescents over 12 years: 1-2 tablets, two, three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 tablets) per day. Do not exceed the recommended dose. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening symptoms, the doctor must be consulted. Elderly: elderly patients must comply with the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency the elimination can be reduced and the dosage should consequently be adequate. Soft capsules. Adults and adolescents over 12 years: 1-2 soft capsules, two, three times a day, preferably on a full stomach. However, do not exceed the dose of 1200 mg (6 soft capsules) per day. Do not exceed the recommended dose. If the use of the medicine is necessary for more than 3 days in adolescents, or in the case of worsening of symptoms, the doctor must be consulted. Elderly: elderly patients must comply with the minimum doses indicated. Patients with renal insufficiency: in the presence of renal insufficiency the elimination can be reduced and the dosage should consequently be adequate. This drug should not be used for more than 7 days. If higher doses are needed or if more prolonged treatment is required, then it is necessary to contact your doctor. Coated tablets and soft capsules should be swallowed without chewing, preferably with a little water. We recommend taking it with or after meals, particularly for people with gastric disorders.
Coated tablets, blister packs of 20 tablets Store at room temperature. Soft capsules, blister packs of 12 or 24 capsules. No storage conditions.
The use of this drug in conjunction with other NSAIDs, including selective cyclooxygenase-2 inhibitors (COX-2), should be avoided due to an increased risk of ulceration or bleeding. Side effects can be minimized with the use of the lowest effective dose for the shortest duration of treatment needed to control symptoms (see the paragraphs below on gastrointestinal and cardiovascular risks). Like other NSAIDs, ibuprofen can mask signs of infection. Pediatric population. In dehydrated adolescents there is a risk of impaired renal function. Senior citizens. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal bleeding and perforation, which can be fatal. Gastrointestinal bleeding, ulceration and perforation. Gastrointestinal haemorrhage, ulceration and perforation that can be fatal have been reported during treatment with all NSAIDs at any time, with or without warning symptoms or a previous history of serious gastrointestinal events. In the elderly and in patients with a history of ulcer, especially after bleeding or perforation, the risk of gastrointestinal bleeding, ulceration or perforation is higher with increased NSAID doses. These patients should start treatment with the lowest available dose. Concomitant use of protective agents (misoprostol or proton pump inhibitors) should be considered for these patients and also for patients who take low doses of acetylsalicylic acid or other drugs that may increase the risk of gastrointestinal events. Patients with a history of gastrointestinal toxicity, particularly the elderly, must report any unusual gastrointestinal symptoms (especially gastrointestinal bleeding), particularly in the initial stages of treatment. Cautelade should be given by patients who simultaneously take drugs that could increase the risk of ulceration or hemorrhage, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors (SSRIs) or platelet aggregation agents such as acetylsalicylic acid. When gastrointestinal bleeding or ulceration occurs in patients taking this medicine, treatment should be stopped. NSAIDs should be administered with caution to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn's disease) as these conditions can be exacerbated. Use with caution in patients with coagulation defects. Cardiovascular and cerebrovascular effects. Adequate monitoring and appropriate instructions are necessary in patients with a history of hypertension and / or mild to moderate congestive heart failure because fluid retention and edema have been reported in association with NSAID treatment. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg / day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). In general, epidemiological studies do not suggest that low doses of ibuprofen (e.g. <= 1200 mg / day) are associated with an increased risk of arterial thrombotic events. Patients with uncontrolled hypertension, congestive heart failure (II-III NYHA class), established ischemic heart disease, peripheral arterial disease and / or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg / day) should be avoided. Careful consideration should also be exercised before initiating long-term treatment for patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking habit), especially if high doses (2400 mg / day) of ibuprofen are needed. Severe skin reactions. Skin gravity reactions, some of them fatal, including exfoliative dermatitis, StevenJohnson syndrome and toxic epidermal necrolysis have been reported very rarely, in association with the use of NSAIDs. In the early stages of therapy, patients seem to be exposed to higher risk; the onset of the reaction occurs in most cases within the first month of treatment. Generalized acute exanthematic pustulosis (PEAG) has been reported in relation to medicinal products containing ibuprofen. Treatment with this drug should be stopped at the first appearance of a skin rash, mucosal lesion or any other sign of hypersensitivity. Kidney effects. When initiating treatment with ibuprofen, caution should be exercised in patients with considerable dehydration. Long-term use of ibuprofen, as with other NSAIDs, has led to renal papillary necrosis and other renal pathological changes. In general, the usual use of analgesics, especially of the associations of different analgesic active ingredients, can lead to permanent kidney lesions with the risk of developing kidney failure (analgesic nephropathy). Renal toxicity has been reported in patients in whom renal leprostaglandins play a compensatory role in maintaining renal perfusion. The administration of NSAIDs in these patients may result in a dose-dependent reduction in the formation of prostaglandins and, as a secondary effect, in renal blood flow. This can quickly lead to kidney failure. The patients most at risk of these reactions are those with reduced kidney function, heart failure, liver dysfunction, the elderly and all those patients who take diuretics and ACE inhibitors. Withdrawal of NSAID therapy is usually followed by recovery of the pretreatment state. In case of prolonged use, monitor renal function particularly in case of diffuse lupus erythematosus. Respiratory disorders. This medicine must be prescribed with caution in patients with bronchial asthma or allergic diseases in progress or past because bronchospasm could occur. The same applies to those subjects who have experienced bronchospasm, after using aspirin or other NSAIDs. Hypersensitivity reactions.
Ibuprofen (like other NSAIDs) should be used with caution in combination with: corticosteroids: increased risk of ulceration or gastrointestinal hemorrhage; Anticoagulants: NSAIDs can increase the effects of anticoagulants such as warfarin. It is appropriate to monitor patients receiving coumarinics; acetylsalicylic acid and other NSAIDs: these substances can increase the risk of adverse reactions affecting the gastrointestinal tract. Concomitant administration of ibuprofen and acetylsalicylic acid is generally not recommended due to the potential increase in side effects. Experimental data suggest that ibuprofen can competitively inhibit the effect of low-dose acetylsalicylic acid on platelet aggregation when the two drugs are administered simultaneously. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No relevant clinical effects are considered likely following occasional ibuprofen use. It is however advisable not to combine ibuprofen with aspirin or other NSAIDs; antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding; diuretics, ACE inhibitors and angiotensin II antagonists: NSAIDs can reduce the effect of diuretics and other antihypertensive drugs. Diuretics can also increase the risk of nephrotoxicity associated with NSAIDs. In some patients with impaired renal function (for example dehydrated or elderly patients) the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the acyclo-oxygenase system can lead to a further deterioration of the function renal, which includes possible acute renal failure, generally reversible. These interactions should be considered in patients taking this medicine concomitantly with ACE angiotensin II inhibitors or antagonists. Therefore, this combination should be administered with caution, especially in elderly patients. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy and periodically thereafter; lithium: the simultaneous administration of lithium and NSAIDs causes increases in lithium levels in the blood due to reduced elimination, with the possibility of reaching the toxic threshold. If such an association is necessary, monitor the lithemia in order to adapt the lithium dosage during simultaneous treatment with ibuprofen; methotrexate: NSAIDs can inhibit the tubular secretion of methotrexate and reduce its clearance with a consequent increase in the risk of toxicity; aminoglycosides: NSAIDs can decrease the excretion of aminoglycosides; cardiac glycosides: NSAIDs can exacerbate heart failure, reduce the rate of glomerular filtration and increase the plasma levels of cardiac glycosides; phenytoin: NSAIDs can lead to an increase in the plasma concentrations of phenytoin; cholestyramine: the concomitant administration of ibuprofen and cholestyramine can reduce the absorption of ibuprofen in the gastrointestinal tract. However, the clinical relevance of this interaction is unknown; ciclosporins: increase the risk of nephrotoxicity with NSAIDs. COX-2 inhibitors and other NSAIDs: concomitant use with other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided for potential additive effect; plant extracts: ginkgo Biloba can increase the risk of bleeding in association with NSAIDs; mifepristone: due to the antiprostaglandin properties of NSAIDs, a decrease in the efficacy of the medicine can theoretically occur. Limited evidence suggests that co-administration of NSAIDs on the day of prostaglandin administration does not adversely affect the effects of mifepristone or prostaglandin on cervical maturation or uterine contractility and does not reduce the clinical efficacy of the medicinal product on termination of pregnancy; quinolone antibiotics: animal data indicate that NSAIDs may increase the risk of seizures associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing seizures; sulphonylureas: NSAIDs can increase the effect of sulphonylureas. Rare cases of hypoglycaemia have been reported in patients receiving sulfonylureas who took ibuprofen; tacrolimus: possible increase in the risk of nephrotoxicity when NSAIDs are administered with tacrolimus; zidovudine: increased risk of blood toxicity in case of co-administration with NSAIDs. There is evidence of an increased risk of hemarthrosis and hematoma in HIV hemophiliac patients concomitantly treated with zidovudine and other NSAIDs; ritonavir: an increase in the concentration of NSAIDs is possible; probenecid: slows down the excretion of NSAIDs with possible increase in their plasma concentrations; sulfinpyrazone: can delay the excretion of ibuprofen; CYP2C9 inhibitors: concomitant administration of ibuprofen and CYP2C9 inhibitors may increase exposure to ibuprofen (CYP2C9 substrate). In a study with voriconazole and fluconazole (CYP2C9 inhibitor), an increased exposure to S (+) - ibuprofen was observed from approximately 80% to 100%.
The side effects observed with ibuprofen are generally common to other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs. Gastrointestinal disorders: the most commonly observed adverse events are gastrointestinal in nature. Gastrointestinal ulceritis, perforation or bleeding may occur, sometimes fatal, particularly in the elderly. Gastrointestinal perforation with the use of ibuprofen has been observed rarely. After administration of this drug, nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, epigastric pain, gastric heartburn, abdominal pain, melena, hematemesis, ulcerative stomatitis, exacerbation of colitis and Crohn's disease have been reported. Less frequently gastritis has been observed. Pancreatitis has also been observed very rarely. Immune system disorders: hypersensitivity reactions have been reported following treatment with NSAIDs. These may consist of: non-specific allergic reaction and anaphylaxis; respiratory tract reactions including asthma, including severe asthma, bronchospasm or dyspnoea or; skin disorders, including rash-type rash, itching, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatitis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Cardiac and vascular disorders: edema and fatigue, hypertension and heart failure have been reported in association with NSAID treatment. Clinical studies suggest that the use of ibuprofen, especially at high doses (2400 mg / day), may be associated with a modest increase in the risk of arterial thrombotic events (e.g. myocardial infarction or stroke). Other adverse events reported less frequently and for which causality has not necessarily been established include. Blood and lymphatic system disorders: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, aplastic anemia and hemolytic anemia Psychiatric disorders: insomnia, anxiety, depression, confusion, hallucinations. Nervous system disorders: headache, paraesthesia, dizziness, drowsiness, optic neuritis. Infections and infestations: aseptic rhinitis and meningitis (especially in patients with pre-existing autoimmune disorders, such as systemic lupus erythematosus and connective disease) with symptoms of neck stiffness, headache, nausea, vomiting, fever or disorientation. Respiratory, thoracic and mediastinal disorders: bronchospasm, dyspnoea, apnea. Eye disorders: rare cases of ocular alteration with consequent visual disturbances, toxic optic neuropathy. Ear and labyrinth disorders: impaired hearing, tinnitus, dizziness. Hepatobiliary disorders: impaired liver function, liver failure, hepatitis and jaundice. Skin and subcutaneous tissue disorders: bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (very rare), photosensitivity reactions and drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) (frequency not known), acute exanthematous pustulosis generalized (PEAG) (frequency not known). Renal and urinary disorders: damage of renal function and toxic nephropathy in various forms, including interstitial nephritis, nephrotic syndrome and renal failure. Systemic diseases and conditions relating to the administration site: malaise, fatigue. Reporting of suspected adverse reactions. The reporting of suspected adverse reactions that occur after authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine.
PREGNANCY AND BREASTFEEDING
Pregnancy: inhibition of the synthesis of prostaglandins can negatively affect pregnancy and / or embryo / fetal development. Data obtained from epidemiological studies suggest an increased risk of diabetes, heart malformation and gastroschisis after the use of a prostaglandin synthesis inhibitor during the first period of pregnancy. The absolute risk of cardiac malformations increased by as much as 1% to around 1,5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre and post implantation loss and embryo-fetal mortality. Furthermore, an increase in the incidence of various malformations, including cardiovascular malformations, has been reported in animals to which prostaglandin synthesis inhibitors have been administered, during the organogenetic period. During the first and second trimester of pregnancy, ibuprofen should not be administered except in strictly necessary cases. When used by women in the process of conception or during the first and second trimester of pregnancy, the dose and duration of treatment should be as low and as short as possible respectively. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors can expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); kidney dysfunction, which can progress to kidney failure with oligo-hydroamnios; the mother and the newborn, at the end of pregnancy, to: possible prolongation of the bleeding time and antiplatelet effect which can also occur at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, ibuprofen is contraindicated during the third trimester of pregnancy. Breastfeeding: in the few studies available to date, NSAIDs can be found in breast milk in very low concentrations. NSAIDs, if possible, should be avoided during breastfeeding. Fertility: the use of diibuprofen can compromise female fertility and is not recommended in women awaiting conception. In women who have difficulty conceiving or who are being investigated on fertility, discontinuation of ibuprofen treatment should be considered.
Delivery is made within 24-72 working hours, Monday to Friday, excluding holidays.
WARNING! In times of high turnout, such as Black Friday, Christmas or Sales, delivery times may increase.
Shipping costs are calculated automatically during the order phase.
- EXPRESS shipping 24-72 working hours
For orders over € 40,00 shipping is free. For orders below € 40,00 the following applies:
- - € 0,00 - € 9,99: € 6,99
- - € 10,00 - € 19,99: € 5,99
- - € 20,00 - € 29,99: € 4,99
- - € 30,00 - € 39,99: € 3,99
- - € 40,00 and up: € 0,00
- Cash on delivery
For orders over € 70,00 shipping is € 3.99. For orders below € 70,00 the following applies:
- - € 0,00 - € 9,99: € 10,98
- - € 10,00 - € 19,99: € 9,98
- - € 20,00 - € 29,99: € 8,98
- - € 30,00 - € 39,99: € 7,98
- - € 40,00 - € 49,99: € 6,98
- - € 50,00 - € 59,99: € 5,98
- - € 60,00 - € 69,99: € 4,98
- - € 70,00 and up: € 3,99
WARNING! If you want to pay cash on delivery, you must select the item twice when ordering, otherwise € 3,99 will be added to the total amount for the service.
- Delivery within 12.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 12.00 on the following day, excluding Saturdays and Sundays.
- € 10.99
- Delivery within 10.00 TNT Express
By placing the order by 12:30 on the current day, delivery will take place by 10.00 on the following day, excluding Saturdays and Sundays.
- € 15.99
- € 7.98
Farmaveloce will deliver your order to the address of your choice throughout Italy, including the islands.
All orders with EXPRESS shipping are entrusted to the courier BRT, GLS, UPS, DHL, FedEx & TNT, Poste Italiane.
farmaveloce.com collects some Personal Data from its Users.
Owner of the Data Privacy
Via Savelli, 10 35129 Padua (Italy)
Email address of the owner: ROAD@ farmaveloce.com
The site: farmaveloce.com
Types of data collected
Among the Personal Data collected, independently or through third parties, there are: Cookies, Data of
use, name, surname, telephone number, VAT number, address, country, postcode, various types
of data, city and tax code.
Full details on each type of data collected are provided in the dedicated sections of this
Personal Data can be freely provided by the User or, in the case of Usage Data,
collected automatically when using the site.
Unless otherwise specified, all data requested by the site are mandatory.
If the User refuses to communicate them, it may be impossible for farmaveloce.com to provide the Service.
In cases where farmaveloce.com indicates some Data as optional, Users are free to
refrain from communicating such Data, without this having any consequence on the availability of the
Service or its operation.
Users who have doubts about which data are mandatory are encouraged to contact
of third party services used by the site, unless otherwise specified, has the purpose of providing the Service
requested by the User, in addition to the additional purposes described in this document and in the Cookie
Policy, if available.
The User assumes responsibility for the Personal Data of third parties obtained, published or shared
through farmaveloce.com and guarantees to have the right to communicate or disseminate them, freeing
the Owner from any liability to third parties.
Mode and place of processing of data collected
Mode of treatment
The Data Controller adopts the appropriate security measures to prevent access, disclosure, the
unauthorized modification or destruction of Personal Data.
The treatment is carried out using IT and / or telematic tools, with methods
organizational and with logic strictly related to the purposes indicated. In addition to the owner, in some
cases, other subjects involved in the organization of the site (staff
administrative, commercial, marketing, legal, system administrators) or external subjects
(such as third party technical service providers, couriers, hosting providers, IT companies,
communication agencies) also appointed, if necessary, Data Processors by the
Holder. The updated list of Managers can always be requested from the Data Controller
Legal basis of the processing
The Holder processes Personal Data relating to the User in the event one of the following conditions exists:
• the User has given consent for one or more specific purposes; Note: in some systems
the Data Controller can be authorized to process Personal Data without the existence of the
User's consent or another of the legal bases specified below, until
the User does not object ("opt-out") to this treatment. This however is not applicable if
the processing of Personal Data is regulated by European legislation on
protection of personal data;
• processing is necessary for the execution of a contract with the User and / or for the execution of
• processing is necessary to fulfill a legal obligation to which the Data Controller is subject;
• processing is necessary for the performance of a public interest task or for
the exercise of public powers with which the Data Controller is invested;
• the processing is necessary for the pursuit of the legitimate interest of the owner or third parties.
In any case, it is always possible to request the Data Controller to clarify the concrete legal basis of each
treatment and in particular to specify whether the treatment is based on the law, provided for by a
contract or necessary to conclude a contract.
The data are processed at the owner's operating offices and in any other place where the parties involved
in the treatment are localized.
For more information, contact the owner.
The User's Personal Data may be transferred to a country other than the one in which the User
is situated. To obtain further information on the place of treatment, the User can refer to
to the section on details on the processing of Personal Data.
The User has the right to obtain information regarding the legal basis for the transfer of Data to
outside the European Union or to an international international law organization
public or consisting of two or more countries, such as the UN, as well as on the measures of
security adopted by the Data Controller to protect the Data.
The User can check whether one of the transfers described above takes place by examining the section
of this document relating to details on the processing of Personal Data or request information from the
Owner by contacting him at the ends shown at the beginning.
The Data are processed and stored for the time required by the purposes for which they were collected.
• Personal Data collected for purposes related to the execution of a contract between the Owner and
the User will be held until the execution of this contract is completed.
• Personal Data collected for purposes related to the legitimate interest of the Owner will be
held until the satisfaction of this interest. The User can get further
information on the legitimate interest pursued by the Data Controller in the relevant sections of
this document or by contacting the owner.
When the treatment is based on the User's consent, the Data Controller can keep Personal Data
longer until such consent is revoked. In addition, the owner could be
obliged to keep Personal Data for a longer period in compliance with an obligation to
law or by order of an authority.
At the end of the retention period, Personal Data will be deleted. Therefore, at the expiration of
this term the right of access, cancellation, rectification and the right to data portability
they can no longer be exercised.
The use of the data collected
User data are collected to allow the owner to provide their services, as well as for
following purposes: Statistics, Interaction with external social networks and platforms, Access to
account on third party services and Contact the User.
To obtain further detailed information on the purposes of the processing and on Personal Data
concretely relevant for each purpose, the User can refer to the relevant sections of
Facebook permissions requested by la farmaveloce.com
Unless otherwise specified
The site may request some Facebook permissions that allow it to perform actions with the account
User's Facebook and to collect information, including Personal Data, from it. This service
allows the site to connect with the User's account on the Facebook social network, provided by
For more information on the following permissions, refer to the documentation of the
The required permits are as follows:
The basic information of the User registered on Facebook which normally includes the following
Data: id, name, image, gender and localization language and, in some cases, the "Friends" of
Facebook. If the User has made publicly available additional data, the same will be available.
Access to private data
Allows access to the User's and friends' private data.
Access to friend lists
Provides access to the lists of friends that the User has created.
Add or edit photos.
Allows the app to add or edit User videos.
Provides access to the list of events in which the User participates.
I like it
Provides access to the list of all the pages that the User has marked with the Like.
Provides access to the User's website.
Details on the processing of Personal Data
The Personal Data are collected for the following purposes and using the following services:
Access to accounts on third party services
This type of service allows the site to collect data from your accounts on third party services and
perform actions with them.
These services are not activated automatically, but require express authorization
Access to the Facebook account (farmaveloce.com)
This service allows the site to connect with the User's account on the social network
Facebook, provided by Facebook, Inc.
Permissions asked: Access to private data, Access to friend lists, Upload photos, Upload of
Videos, Events, Likes and Website.
Contact the user
By filling in the contact form with their Data, the User consents to their use for
respond to requests for information, quotes, or any other kind indicated
from the form header.
Personal data collected: post code, city, tax code, surname, address, country, name, number of
telephone, VAT number and various types of data.
Interaction with external social networks and platforms
This type of service allows you to interact with social networks, or with other platforms
external, directly from the pages of the site
The interactions and information acquired from the site are in any case subject to the settings
User privacy related to each social network.
In the event that an interaction service with social networks is installed, it is possible that, too
if Users do not use the service, it collects traffic data relating to the pages in
which it is installed on.
Like button and social widgets for Facebook (Facebook, Inc.)
The "Like" button and Facebook social widgets are social interaction services
Facebook network, provided by Facebook, Inc.
Personal Data collected: Cookies and Usage Data.
The services contained in this section allow the Data Controller to monitor and
analyze traffic data and are used to keep track of User behavior.
Google Analytics (Google Inc.)
Google Analytics is a web analysis service provided by Google Inc. ("Google"). Google uses i
Personal data collected for the purpose of tracking and examining the use of farmaveloce.com,
compile reports and share them with other services developed by Google.
Google may use the Personal Data to contextualise and personalize the advertisements of the
own advertising network.
Personal Data collected: Cookies and Usage Data.
More information on Personal Data
Selling goods and services online
The Personal Data collected is used for the provision of services to the User or for the sale of
products, including payment and possible delivery. Personal Data collected to perfect the
payment may be those relating to the credit card, the current account used for the
bank transfer or other expected payment instruments. Payment data collected by
farmaveloce.com depend on the payment system used.
Users may exercise certain rights with reference to the Data processed by the Data Controller.
In particular, the User has the right to:
• withdraw consent at any time. The User can withdraw consent to the treatment
of their Personal Data previously expressed.
• object to the processing of their data. The user can object to the processing of their data
when it occurs on a legal basis other than consent. Further details on the law
of opposition are indicated in the section below.
• access their Data. The User has the right to obtain information on the Data processed by the
Holder, on certain aspects of the treatment and to receive a copy of the Data processed.
• verify and request correction. The User can verify the correctness of their Data
and request its updating or correction.
• obtain the limitation of the treatment. When certain conditions are met,
the User can request the limitation of the processing of their Data. In this case the Owner
will not process the Data for any other purpose other than their conservation.
• obtain the cancellation or removal of their Personal Data. When they recur
certain conditions, the User can request the deletion of their Data by the
• receive your data or have it transferred to another holder. The User has the right to receive i
own Data in structured format, commonly used and readable by automatic device and, where
technically feasible, to obtain the transfer without hindrance to another owner. This
provision is applicable when the Data are processed with automated tools and the
processing is based on the User's consent, on a contract of which the User is a party or on
contractual measures connected to it.
• propose a complaint. The User can lodge a complaint with the supervisory authority of the
protection of personal data competent or to act in court.
Details on the right of opposition
When Personal Data are processed in the public interest, in the exercise of public powers referred to
the Owner is invested or to pursue a legitimate interest of the Owner, the Users have
right to object to processing for reasons related to their particular situation.
Users are reminded that if their data were processed for direct marketing purposes,
can oppose the treatment without giving any reason. To find out if the owner deals
data for direct marketing purposes Users can refer to the respective sections of
How to exercise the rights
To exercise the User's rights, Users can address a request to the ends of
contact of the Owner indicated in this document. Requests are filed free of charge and
processed by the Owner as soon as possible, in any case within a month.
Additional information on treatment
Defense in court
The User's Personal Data may be used by the Owner in court or in stages
preparatory to its possible establishment for the defense against abuse in the use of
farmaveloce.com or related Services by the User.
The User declares to be aware that the Data Controller may be obliged to reveal the Data
by order of the public authorities.
farmaveloce.com could provide the User with additional and contextual information
concerning specific Services, or the collection and processing of Personal Data.
Log System and Maintenance
For needs related to the operation and maintenance of the site and any third party services from
it used could collect system logs, that is files that record the interactions and that
they may also contain Personal Data, such as the User IP address.
Information not contained in this Policy
Further information in relation to the processing of Personal Data may be requested in
at any time to the Data Controller using the contact details.
Response to "Do Not Track" requests
The site does not support "Do Not Track" requests.
To find out if any third-party services used support them, the User is invited to
consult the respective privacy policies.
any time giving information to Users on this page and, if possible, on the site
as well as, if technically and legally feasible, by sending a notification to Users through one
of the contact details held by the Owner. Therefore, please consult regularly
this page, referring to the date of last modification indicated at the bottom.
If the changes affect treatments whose legal basis is consent, the Owner
will collect the User's consent again, if necessary.
Definitions and legal references
Personal Data (or Data)
It constitutes personal data any information that, directly or indirectly, also in
link with any other information, including an identification number
personal, makes a natural person identified or identifiable.
Data of Use
This is the information collected automatically through the site (also by party applications
third parties integrated into the site), including: IP addresses or domain names of the computers used
by the User who connects with the site, the addresses in URI (Uniform Resource Identifier) notation,
the time of the request, the method used to forward the request to the server, the file size
obtained in response, the numeric code indicating the status of the response from the server (successful, error,
etc.) the country of origin, the characteristics of the browser and operating system used by the
visitor, the various temporal connotations of the visit (for example the time spent on
each page) and the details of the itinerary followed within the Application, with
particular reference to the sequence of the pages consulted, to the parameters relating to the system
operating environment and the IT environment of the User.
The individual who uses the site which, unless otherwise specified, coincides with the interested party.
The natural person to whom the Personal Data refers.
Data Processor (or Manager)
The natural person, legal entity, public administration and any other entity that processes data
Data Controller (or Owner)
The natural or legal person, public authority, service or other body which, individually or
together with others, it determines the purposes and means of the processing of personal data and the tools
adopted, including the security measures relating to the operation and use of
farmaveloce.com. Unless otherwise specified, the Data Controller is the
owner of farmaveloce.com.
farmaveloce.com (or this Application)
The hardware or software tool through which the Personal Data of the
The service provided by the site as defined in the relative terms (if any) on this
site / application.
European Union (or EU)
Unless otherwise specified, any reference to the European Union contained in this
document is intended to be extended to all current member states of the European Union and Space
Small portion of data stored in the User's device.
This privacy statement is drawn up on the basis of multiple legislative systems, including articles 13 and 14 of the Regulation (EU) 2016 / 679.
Unless otherwise specified, this privacy statement only concerns the site.
RIGHT OF WITHDRAWAL
Deadline for withdrawal
The Consumer has a period of fourteen days to withdraw from the contract without having to provide any reason.
The aforementioned term starts:
a) if a service is offered from the day of the conclusion of the contract
b) in the case of sale of a product, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the goods or:
• in the case of multiple goods ordered by the Consumer through a single order and delivered separately, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last good;
• in the case of delivery of an asset consisting of lots or multiple pieces, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the last lot or piece;
• in the case of contracts for the periodic delivery of goods during a certain period of time, from the day on which the Consumer or a third party, other than the carrier and designated by the Consumer, acquires physical possession of the first asset.
Obligations of the pharmacy The pharmacy, following the withdrawal of the consumer:
<br>• immediately communicates to the Consumer a confirmation of receipt, on a durable medium, of the Withdrawal exercised;
• reimburses the same all payments received, not including delivery costs, without undue delay and in any case within fourteen days from the day of the communication of the Right of Withdrawal.
• the pharmacy reimburses using the same payment method used by the consumer, unless otherwise agreed after payment.
Obligations for the Consumer
The shipping costs for the return of the products received must be paid by the Consumer, which must be shipped within fourteen days from the date on which he communicated his decision to withdraw from the contract (the deadline is respected if the Consumer returns the goods before the expiry of the fourteen day period).
The substantial integrity of the asset is an essential condition for exercising the right of withdrawal. The Product must therefore be kept with normal diligence and returned intact, complete in all its parts, fully functional and free of signs of wear or dirt.
Exceptions to the Right of Withdrawal - products for which the application of the Right of Withdrawal is excluded
The right of withdrawal cannot be exercised:
a) in case of purchase of medicines and medical devices
b) supply of food, drinks or other goods intended for current consumption in the family and physically supplied by a professional in frequent and regular rounds to the consumer's home, residence or workplace
c) in the case of purchases of less than 50 euros (unless the total consideration that the Consumer must pay regardless of the amount of the individual contracts exceeds 50 euros);
d) in the case of a contract for a service after the complete provision of the service if the execution of the contract began with the express agreement of the Consumer;
e) in case of supply of goods made to measure or clearly personalized;
f) in the event of the supply of goods which are liable to deteriorate or expire rapidly;
g) in the case of the supply of sealed goods that do not lend themselves to be returned for reasons of hygiene or connected to the protection of health and have been opened after delivery;
h) in case of supply of goods which after delivery are by their nature inseparably mixed with other ben.
In the event of a lack of conformity, or delivery of goods that present defects or defects or are different from that provided in the sales contract, i.e. unsuitable for the use for which a good of the same is usually used
type, which differs from the description published on the site or which does not manifest the promised qualities, the provisions of the Legal Guarantee as per articles 128 and following of Legislative Decree 205/2006 (Consumer Code).
Any breakdowns or malfunctions caused by accidental events or by Customer's liability or by a use of the product not in accordance with its intended use and / or as foreseen in the technical documentation attached to the product are excluded from the scope of the Legal Guarantee.
The pharmacy is responsible when the lack of conformity occurs within two years from the delivery of the goods, unless a conventional guarantee is provided after this deadline. In the case of the sale of used goods, the guarantee referred to in the previous paragraph may be limited to a period of time in any case
not less than one year.
The Consumer is obliged to report the defect or defect to me quickly within two months of discovery (unless the sector has recognized or concealed the existence of the defect).
It is assumed that the defects of conformity that occur within six months of delivery of the goods already existed on that date, unless this hypothesis is incompatible with the nature of the asset or with the nature of the defect of
The direct action to assert defects not maliciously concealed by the seller is prescribed within twenty-six months from the delivery of the goods (the Consumer who is agreed for the execution of the contract can nevertheless always assert the rights referred to in this article provided that the lack of conformity has been reported within two months of discovery and before the expiry of the two years from delivery).
In the event of a lack of conformity, the Consumer can request, at no cost (including shipping), the restoration by repair or replacement, at his choice, unless the remedy is objectively impossible or excessively expensive compared to the other.
The above remedy is to be considered excessively expensive if it imposes unreasonable costs on the store compared to the other, taking into account:
a) the value that the asset would have if there were no lack of conformity;
b) the extent of the lack of conformity;
c) the possibility that the alternative remedy can be tried without significant inconvenience for the Consumer.
Repairs or replacements will be carried out within a reasonable time from the request and must not cause significant inconvenience to the Consumer, taking into account the nature of the goods and the purpose for which it was purchased.
The Consumer can request, at his choice, an appropriate price reduction or the termination of the contract if one of the following situations occurs:
a) repair and replacement are impossible or excessively expensive;
b) the seller did not replace within a reasonable time;
c) the replacement or repair previously carried out has caused significant inconvenience to the Consumer.
The use of the asset is taken into account when determining the amount of the reduction or the amount to be returned.
After reporting the lack of conformity, the seller can offer the consumer any other available remedy, with the following effects:
a) if the Consumer has already requested a specific remedy, the seller remains obliged to implement it, with the necessary consequences regarding the commencement of the appropriate term for repairs or replacements, unless the Consumer accepts the proposed alternative remedy;
b) if the Consumer has not already requested a specific remedy, the Consumer must accept the proposal or reject it by choosing another remedy pursuant to this article.
A slight lack of conformity, for which it has not been possible or is excessively burdensome to carry out the remedies of repair or replacement, does not give the right to terminate the contract.
The Legal Guarantee is limited to purchases made by Consumers. As regards subjects other than Consumers, the provisions of the Consumer Code apply to Articles 1490 et seq.
Conventional Manufacturer Warranty
The products sold on the Site may, depending on their nature, be covered by a conventional warranty issued by the manufacturer ("Conventional Warranty"). The customer can only enforce this guarantee against the manufacturer. The duration, the extension, also territorial, the conditions and methods of use, the types of damage / defects covered and any limitations of the Conventional Warranty depend on the individual manufacturer and are indicated in the so-called warranty certificate contained in the product packaging. The Conventional Guarantee is voluntary in nature and does not add, replace, limit or prejudice or exclude the Legal Guarantee.
Payment and security
Your payment information is processed securely. We do not store credit card details nor do we have access to your credit card information.
What is lactoferrin?
Lactoferrin, also known as lactotransferrin is a multifunctional globular protein with antimicrobial activity, both bactericidal and fungicidal.
is the successful formula of Natural Point, which has been committed for over 25 years to providing natural support to support people's wellbeing.